Trump announces trade deal with EU following months of negotiations
HONG KONG - Aptorum Group Limited (NASDAQ:APM), a biotech firm specializing in the development of treatments for diseases with unmet medical needs, has received a notice of non-compliance from Nasdaq. The notice, dated April 15, 2025, indicates that Aptorum’s share price has fallen below the minimum bid price of $1 required for continued listing on the Nasdaq Stock Market. According to InvestingPro data, the company’s stock has declined nearly 86% over the past year, with its current market capitalization standing at just $7.04 million.
The current status of Aptorum’s shares on the Nasdaq is not immediately impacted by this notification. The company has been given a grace period of 180 calendar days, until October 14, 2025, to regain compliance with the listing requirements. If the company’s shares do not meet the minimum bid price requirement within this period, Aptorum Group may face delisting from the exchange. Recent data shows some positive momentum, with the stock posting a 46% gain over the past week, though it remains significantly below its 52-week high of $7.88.
Aptorum Group has stated its intention to consider all possible options to meet the Nasdaq’s requirements, including a potential reverse stock split. The company has expressed its commitment to maintaining its Nasdaq listing and assures that it will take reasonable steps to comply with the exchange’s standards within the given timeframe.
This development comes as the pharmaceutical company continues its efforts in the discovery, development, and commercialization of novel therapeutics. The company’s focus remains on addressing the challenges of diseases that currently lack effective treatments.
The forward-looking statements included in the company’s press release carry risks and uncertainties, and there is no guarantee that the company’s plans to regain compliance will be successful. Actual results may differ from the company’s projections. InvestingPro analysis reveals several challenges, including significant debt burden and rapid cash burn, though analysts expect sales growth this year. For detailed insights and 13 additional ProTips about APM’s financial health and prospects, subscribers can access the comprehensive Pro Research Report.
The information in this article is based on a press release statement from Aptorum Group Limited.
In other recent news, Andean Precious Metals reported record revenues of $254 million for the fourth quarter of 2024, with a net income of $19.2 million, translating to $0.12 per share. The company achieved a record adjusted EBITDA of $62.9 million, highlighting a strong financial performance. Andean Precious Metals also shared optimistic projections for 2025, expecting consolidated gold equivalent production to range between 102,900 and 117,200 ounces. The company successfully integrated Golden Queen into its operations, contributing significantly to its financial success. Additionally, Andean Precious Metals completed an important milestone by uplisting to the Toronto Stock Exchange, enhancing its visibility in the capital markets. The company maintains a strong cash position with $62.4 million in cash and equivalents. Despite these achievements, Andean Precious Metals faces challenges such as managing operational costs and navigating market volatility. The company plans to focus on operational efficiencies and exploration opportunities in the coming year.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.